One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Early diagnosis of familial melanoma: challenging but feasible
A. Lallas
doi : 10.1111/jdv.17104
Volume 35, Issue 2 p. 274-275
Early diagnosis of melanoma is almost always a challenging task. This is because the characteristic ABCD morphologic criteria become gradually visible to the naked eye as melanoma evolves, but might be not yet detectable when melanoma is still small. This problem has been resolved, to a large extend, by dermatoscopy, which enables the visualization of the morphologic asymmetry of the tumour at an earlier stage.1 However, even with dermatoscopy, early melanoma recognition remains challenging in some scenarios. For example, some melanomas are featureless (lack specific features) not only clinically but also dermatoscopically. Or, in individuals with multiple atypical moles, melanoma might be hidden among the plethora of atypical nevi. Or even more, when both confusing factors co-exist (featureless melanoma in an individual with numerous atypical moles), rendering the challenge too hard to solve. And, obviously, the potential consequences of our diagnostic limitations are even more relevant in individuals being at increased risk to develop melanoma.
Outcome assessment in dermatology: a tree in need of pruning
A. Ragamin, T. Nijsten
doi : 10.1111/jdv.17103
Volume 35, Issue 2 p. 276-277
Clinical Trials in medicine is a multi-billion dollar industry, but exposes patients to risks and uncertainty, and provide an ever-increasing amount of information to clinicians. The costs per individual trial, number of different diseases studied, the number of participating international centres and patients, and complexity of study designs are increasing. The outcome of the studies has evolved as well and is now including more detailed clinical outcomes, patient-reported outcomes (e.g. effect on specific symptoms, health-related quality of life and treatment satisfaction), drug tolerability and safety, and costs. To summarize and compare the findings of clinical studies in (network) meta-analysis, it is important that the study designs are at least comparable and ideally identical. However, as expected in situations of exponential growth, we lost oversight of the different outcomes and their definitions used in the clinical studies in dermatology. We have neglected the trees in the orchard while picking low-hanging fruit.
Pioneers in Dermatology and Venereology: an interview with Professor Jean Hilaire Saurat
J.H. Saurat
doi : 10.1111/jdv.17115
Volume 35, Issue 2 p. 278-280
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
A. Nast, C. Smith, P.I. Spuls, G. Avila Valle, Z. Bata-Cs?rg?, H. Boonen, E. De Jong, I. Garcia-Doval, P. Gisondi, D. Kaur-Knudsen, S. Mahil, T. M?lk?nen, J.T. Maul, S. Mburu, U. Mrowietz, K. Reich, E. Remenyik, K.M. R?nholt, P.G. Sator, M. Schmitt-Egenolf, M. Sikora, K. Str?mer, O. Sundnes, D. Trigos, G. Van Der Kraaij, N. Yawalkar, C. Dressler
doi : 10.1111/jdv.16926
Volume 35, Issue 2 p. 281-317
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.
Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
A.Y. Finlay, P.V. Chernyshov, L. Tomas Aragones, A. Bewley, A. Svensson, L. Manolache, S. Marron, A. Suru, F. Sampogna, M.S. Salek, F. Poot
doi : 10.1111/jdv.16914
Volume 35, Issue 2 p. 318-328
The pharmaceutical approach to skin disease has been hugely successful, but despite effective drugs being available and used, there are still vast numbers of people who continue to have some level of persisting skin disease and continue to experience quality of life (QoL) impairment. So the question that needs to be answered, while we await further advances in our drug-based armamentarium, is how can we improve patients’ QoL, beyond drugs? A working group was formed from members of the EADV Task Force on QoL and Patient Oriented Outcomes. Participants were asked to suggest all the ways in which they considered patients’ QoL may be improved beyond medicines. Four groups of management approaches that may improve QoL in dermatology were identified: interventions within the dermatology service (hospitalization, multidisciplinary teams, patch testing and establishing relevant allergens and education), external services (corrective make-up, climatotherapy and balneotherapy), psychological (psychological intervention, cognitive therapy, hypnosis), lifestyle (lifestyle behavioural changes, religion and spirituality and music). The ultimate aim of therapy is to eradicate a disease in an individual and return the person’s life to normal. But until the day comes when this has been achieved for every skin disease and for every patient there will be a need to support and assist many patients in additional non-pharmaceutical ways. These ‘adjuvant’ approaches receive too little attention while dermatologists and researchers strive for better pharmacological therapy. The different ways in which patients may benefit have been reviewed in our paper, but the reality is that most have a very poor evidence base. The research challenges that we have to meet are to identify those approaches that might be of value and to provide evidence for their optimal use. In the meantime, clinicians should consider the use of these approaches where QoL remains impaired despite optimal use of standard therapy.
Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach
T. Tsakok, T. Rispens, P. Spuls, A. Nast, C. Smith, K. Reich
doi : 10.1111/jdv.16980
Volume 35, Issue 2 p. 329-337
With biologic drugs dominating the therapeutic space for severe immune-mediated inflammatory disease, it is critical for clinicians to be familiar with the concept of drug immunogenicity, with the potential for our patients to develop antidrug antibodies (ADA) of clinical relevance. Whilst there are clear differences between different therapeutic biologics in terms of reported ADA rates, there is no accepted dermatology guideline or grouping of drugs by risk of clinically relevant ADA, nor a consensus on approach to ADA management. This is partly because making valid comparisons of immunogenicity across drugs is fundamentally flawed: the differing types of ADA assay, trial design and included patient population – as well as the molecular structure of the biologic molecules themselves – are all highly influential on reported ADA prevalence and impact on clinical response. Therefore, the first part of this article aims to give an overview of ADA that also clarifies common misconceptions on the subject, whilst the second part of this article outlines Phase III immunogenicity data on commonly used biologics for psoriasis, the most common dermatological indication. Based on this, and acknowledging current limitations in available evidence, we propose a working categorization of biologics together with a broad approach to management: Group 1 – biologics with higher risk of clinically relevant ADA; Group 2 – biologics with lower risk of clinically relevant ADA; and Group 3 – biologics with no established risk of clinically relevant ADA. However, these groupings represent a working concept only; more research is required, using comparable ADA assays and consistent reporting of related outcomes. Finally, there is an urgent need for better characterization of individuals at particular risk of developing ADA to inform future clinical decision-making.
Is Cutibacterium (previously Propionibacterium) acnes a potential pathogenic factor in the aetiology of the skin disease progressive macular hypomelanosis?
A. McDowell, J. McLaughlin, A.M. Layton
doi : 10.1111/jdv.16789
Volume 35, Issue 2 p. 338-344
Progressive macular hypomelanosis (PMH) is a skin condition that normally causes symmetrically distributed hypopigmented macules on the front and back of the trunk, but rarely the face. To date, the pathophysiology of the condition is not well understood, but a role for the anaerobic skin bacterium Cutibacterium (previously Propionibacterium) acnes in the development of the disease has been proposed due to its sole presence within lesional, but not normal peri-lesional, skin. The success of antimicrobials in the treatment of PMH also provides circumstantial evidence that this association may be causal, although this is still to be proven. More recent culture and metagenomic typing studies indicate that strains of C. acnes subsp. elongatum (type III) may be important in the aetiology of the condition, which would help to explain why PMH does not normally affect the face since such strains are rarely present there, and why no association between this condition and acne vulgaris is found; acne appears to primarily involve type IA1 strains from C. acnes subsp. acnes (type I). In this review, we summarize current knowledge on the relationship between C. acnes and PMH, and re-examine previous challenges to the view that the bacterium plays a role in the condition against the backdrop of newly emerged data.
Sexual impairment in patients with hidradenitis suppurativa: a systematic review
C. Cuenca-Barrales, T. Montero-V?lchez, J.C. Szepietowski, L. Matusiak, A. Molina-Leyva
doi : 10.1111/jdv.16726
Volume 35, Issue 2 p. 345-352
Hidradenitis suppurativa (HS) can cause considerable impact on several aspects of quality of life. Sexuality is a central aspect of quality of life. In recent years, there has been an increase in the number of articles on HS and sexuality. To achieve our aim of synthesizing the available scientific evidence on HS and sexual health, we conducted a systematic review in February 2020. The clinical databases used included Medline and Embase. All types of epidemiological articles were included; reviews, guidelines, protocols, conference abstracts and case report articles were excluded. Eleven studies were included for review, representing 42 729 patients with HS. The most common study design was cross-sectional with or without comparison group(s), conducted in an outpatient setting or through surveys. Prevalence of sexual dysfunction ranged between 51–62%, and in the case of erectile dysfunction, a specific kind of sexual dysfunction affecting penile erection, it ranged from between 52% and 60% of patients studied using validated questionnaires. Potential risk factors for sexual dysfunction among men and women were identified, mainly related to disease activity, symptoms and partners. Mood disorders like depression and anxiety appear to be associated with sexual dysfunction. Women were more affected by sexual distress. HS patients with sexual dysfunction had a decreased overall quality of life. With respect to treatment, surgery did not improve sexual function and there is no scientific evidence regarding medical treatments. Patients stated that they would like to treat their sexual problems with healthcare professionals. In conclusion, sexual and erectile dysfunction are common in HS patients, and negatively affect their quality of life. There are clinical factors potentially associated with this which should be identified and treated by dermatologists in the comprehensive care of HS patients. Prospective studies are needed to provide more scientific evidence on this unmet need.
Skin cancer risk in CHEK2 mutation carriers
A.N. Bui, N.R. LeBoeuf, V.E. Nambudiri
doi : 10.1111/jdv.16729
Volume 35, Issue 2 p. 353-359
CHEK2 mutations have been linked with an increased risk of breast cancer. A unique challenge for oncodermatologists and oncologists is in the monitoring and counselling of patients regarding skin cancer risk due to CHEK2 mutation carrier status. In this review, we highlight current information in the literature on the risk of melanoma and non-melanoma skin cancers in CHEK2 mutation carriers. On the molecular level, CHEK2 is a cell cycle regulator that has been linked to cancer pathogenesis, though evidence from clinical studies regarding skin cancer risk has been inconsistent and conflicting. For melanoma, one study has demonstrated a statistically significant twofold risk of melanoma in individuals with CHEK2 mutations, particularly the CHEK2*1100delC variant. Five other studies did not show an association. For non-melanoma skin cancer, fewer data exist, with one prevalence study of CHEK2 mutations in a cohort of patients with basal cell carcinomas. Although there are currently no known studies of CHEK2 and cutaneous squamous cell carcinoma (SCC), data from other disciplines associating CHEK2 with head and neck SCCs are emerging. Overall, while there is currently not enough evidence to make conclusive statements regarding increased risk of melanoma and non-melanoma skin cancers in CHEK2 carriers, a molecular mechanism associating the mutation with cutaneous malignancy pathogenesis is evident, and further work is needed. Patient with CHEK2 mutations may benefit from screening dermatologic examinations with particular attention to skin cancers.
Intermittent use of biologic agents for the treatment of psoriasis in adults
A. Al-Hammadi, Z. Ruszczak, G. Magari?os, C.-Y. Chu, Y. El Dershaby, N. Tarcha
doi : 10.1111/jdv.16803
Volume 35, Issue 2 p. 360-367
Current clinical recommendations suggest that continuous treatment of moderate-to-severe psoriasis with biologic agents is more effective than intermittent treatment in terms of achieving remission and maintaining it. Intermittent treatment, however, may provide an alternative approach in patients unwilling or unable to maintain a continuous regimen, such as those who would prefer a ‘treatment vacation’ after achieving long-term remission, those who require treatment cessation owing to adverse events, and where insurance arrangements do not provide sufficient cover for continuous treatment. We conducted a literature search of PubMed to identify publications reporting data on the efficacy and safety of intermittent treatment with biologic agents in adults with psoriasis, specifically the use of inhibitors of tumour necrosis factor (adalimumab, certolizumab pegol, etanercept and infliximab), interleukin (IL)-12/IL-23 (ustekinumab), IL-23 (guselkumab) and IL-17 (brodalumab, ixekizumab and secukinumab). From our search, we identified 18 relevant publications reporting the intermittent use of the biologic therapies of interest: five described etanercept, three described adalimumab, two each described infliximab, ixekizumab or ustekinumab, and one each described certolizumab pegol, guselkumab, brodalumab and secukinumab. In general, there were large proportions of patients (?60%) who were able to re-establish disease control (as defined by each study) following re-treatment, and the safety profiles of the various agents during re-treatment were as anticipated from their profiles observed during continuous dosing. The exception to these general findings was infliximab, which showed the lowest rate of efficacy-endpoint achievement (25% and 38% in two dosing groups evaluated) as well as a higher incidence of adverse infusion reactions compared with continuous dosing. In conclusion, the use of biologic agents in psoriasis is changing and current clinical data suggest that intermittent treatment may provide an effective and well-tolerated option for certain patients.
CTNNBIP1 modulates keratinocyte proliferation through promoting the transcription of ?-catenin/TCF complex downstream genes
C. Wang, H. Wang, Y. Peng, B. Zeng, Y. Zhang, X. Tang, L. Mi, Y. Pan, Z. Yang
doi : 10.1111/jdv.16725
Volume 35, Issue 2 p. 368-379
During psoriasis initiation and development, deregulations in signalling pathways and gene expression are observed.
Clinical features of subungual melanoma according to the extent of Hutchinson’s nail sign: a retrospective single-centre study
C. Sohng, M.H. Han, D. Park, K.D. Park, Y.H. Jang, W.J. Lee, S.J. Lee, J.Y. Kim
doi : 10.1111/jdv.16762
Volume 35, Issue 2 p. 380-386
Hutchinson’s nail sign (HS) is among the diagnostic criteria for subungual melanoma (SUM). However, there is minimal evidence supporting the overall clinical significance of HS in SUM.
The predictive and prognostic significance of cell-free DNA concentration in melanoma
R. V?raljai, S. Elouali, S.S. Lueong, K. Wistuba-Hamprecht, T. Seremet, J.T. Siveke, J.C. Becker, A. Sucker, A. Paschen, P.A. Horn, B. Neyns, B. Weide, D. Schadendorf, A. Roesch
doi : 10.1111/jdv.16766
Volume 35, Issue 2 p. 387-395
Melanoma is the leading cause of skin cancer-related deaths worldwide. While there have been significant improvements in the treatment of advanced melanoma in the past decade, biomarker development lagged behind.
Genomic profiling of late-onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome
O. Hasan Ali, A.A. Yurchenko, O. Pavlova, A. Sartori, D. Bomze, R. Higgins, S.S. Ring, F. Hartmann, D. Bühler, F.R. Fritzsche, W. Jochum, A.A. Navarini, A. Kim, L.E. French, E. Dermitzakis, A.M. Christiano, D. Hohl, D.R. Bickers, S.I. Nikolaev, L. Flatz
doi : 10.1111/jdv.16767
Volume 35, Issue 2 p. 396-402
Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant genetic disorder. It is commonly caused by mutations in PTCH1 and chiefly characterized by multiple basal cell carcinomas (BCCs) developing prior to the age of 30 years. In rare cases, NBCCS presents with a late onset of BCC development.
Dermoscopy comparative approach for early diagnosis in familial melanoma: influence of MC1R genotype
C. Longo, V. Barquet, E. Hernandez, A.A. Marghoob, M. Potrony, C. Carrera, P. Aguilera, C. Badenas, J. Malvehy, S. Puig
doi : 10.1111/jdv.16679
Volume 35, Issue 2 p. 403-410
MC1R polymorphisms interact with CDKN2A mutations modulating melanoma risk and contribute to a less suspicious clinical and dermoscopic appearance of melanomas. Different strategies, including dermoscopic comparative approach and digital monitoring, are used for the melanoma diagnosis in this context.
Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database
C. Grodner, E. Sbidian, A. Weill, M. Mezzarobba
doi : 10.1111/jdv.16566
Volume 35, Issue 2 p. 411-416
Psoriasis is one of the most frequent chronic inflammatory dermatoses in the world. Data on the prevalence of psoriasis in adults differ depending on the study.
Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact
N.M. Golbari, J.M. van der Walt, A. Blauvelt, C. Ryan, P. van de Kerkhof, A.B. Kimball
doi : 10.1111/jdv.16966
Volume 35, Issue 2 p. 417-421
Psoriasis severity is usually evaluated using quantitative and qualitative measures, including per cent body surface area (BSA) involvement, the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI), a patient-reported questionnaire. However, standardized definitions for psoriasis severity categories have not been well established. A PASI of 10 or 12 has remained the minimal severity threshold defining eligibility for psoriasis treatments. In the present study, the validity of this cut-off was re-evaluated in the context of quality of life.
Definition of minimal disease activity in psoriasis
G. Carretero, J.M. Carrascosa, L. Puig, J.L. S?nchez-Carazo, A. L?pez-Ferrer, P. Cueva, C. Soria, R. Rivera, I. Belinch?n, on behalf of The Psoriasis Group of the Spanish Academy of Dermatology, Venereology
doi : 10.1111/jdv.16564
Volume 35, Issue 2 p. 422-430
To generate an operational definition to adequately reflect the construct ‘Minimal Disease Activity (MDA)’ in psoriasis.
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results
M. Augustin, E. Dauden, U. Mrowietz, M.P. Konstantinou, S. Gerdes, K. Kingo, J.C. Szepietowski, J.L. Perrot, A. Cuccia, M. Rissler, S. Gathmann, C. Sieder, R. Orsenigo, P. Jagiello, T. Bachhuber
doi : 10.1111/jdv.16632
Volume 35, Issue 2 p. 431-440
Psoriatic disease is associated with considerable impairment of quality of life (QoL). The PROSE study (NCT02752776) investigated the impact of secukinumab treatment on patient-reported outcomes (PRO) in patients with moderate to severe psoriasis stratified by their treatment history.
Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial
G. Holzer, M. Hoke, S. Sabeti-Sandor, T. Perkmann, A. Rauscher, B. Strassegger, S. Radakovic, A. Tanew
doi : 10.1111/jdv.16635
Volume 35, Issue 2 p. 441-449
The effect of adalimumab and fumaric acid esters (FAE) on the cardiovascular risk associated with psoriasis has only been investigated scarcely in randomized controlled studies.
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3
R.B. Warren, J.B. Hansen, K. Reich, C. Paul, L. Puig
doi : 10.1111/jdv.16816
Volume 35, Issue 2 p. 450-457
Modern biologics achieve complete skin clearance [100% improvement in psoriasis area and severity index (PASI 100)] in 30–45% of psoriasis patients. Cumulative benefit considering rapidity, frequency and sustainability of response has not been thoroughly investigated.
IDQoL, CDLQI and the 45-item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan: a group discussion study
M. Gabes, C. Apfelbacher, for the quality of life working group of the Harmonising Outcome Measures for Eczema (HOME) initiative
doi : 10.1111/jdv.16848
Volume 35, Issue 2 p. 458-463
The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed that quality of life should be measured in all atopic eczema clinical trials. Various candidate instruments exist for this domain but their content validity in atopic eczema is largely unclear.
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
A.S. Paller, E.C. Siegfried, E.L. Simpson, M.J. Cork, B. Lockshin, M.P. Kosloski, M.A. Kamal, J.D. Davis, X. Sun, G. Pirozzi, N.M.H. Graham, A. Gadkari, L. Eckert, M. Ruddy, A. Bansal
doi : 10.1111/jdv.16928
Volume 35, Issue 2 p. 464-475
Dupilumab has demonstrated efficacy and acceptable safety in adults and children (aged 6–17 years) with moderate-to-severe atopic dermatitis (AD), but effective systemic therapy with a favorable risk–benefit profile in younger children remains a significant unmet need.
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
T. Bieber, J.P. Thyssen, K. Reich, E.L. Simpson, N. Katoh, A. Torrelo, M. De Bruin-Weller, D. Thaci, R. Bissonnette, M. Gooderham, J. Weisman, F. Nunes, D. Brinker, M. Issa, K. Holzwarth, M. Gamalo, E. Riedl, J. Janes
doi : 10.1111/jdv.16948
Volume 35, Issue 2 p. 476-485
Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in late-stage development for adult patients with moderate-to-severe AD.
Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris
N. Ernst, M. Friedrich, K. Bieber, M. Kasperkiewicz, N. Gross, C.D. Sadik, D. Zillikens, E. Schmidt, R.J. Ludwig, K. Hartmann
doi : 10.1111/jdv.16780
Volume 35, Issue 2 p. 486-492
Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are common autoimmune bullous dermatoses (AIBD) characterized by blisters and erosions. Treatment options are limited and often insufficient. Immune checkpoint receptors play critical roles in immune homoeostasis and self- tolerance. Targeting checkpoint receptors is highly efficient in treatment of various cancers, but often also associated with autoimmune side effects.
Macrophage-activating lipopeptide-2 and corticotropin-releasing hormone stimulate the inflammatory signalling in human sebocytes through activation of stearoyl-CoA desaturase and fatty acid desaturase 2
C.C. Zouboulis, S. Angres
doi : 10.1111/jdv.17016
Volume 35, Issue 2 p. 493-501
The macrophage-activating lipopeptide-2 (MALP-2) activates cells carrying a functional Toll-like receptor (TLR)-2/6. Human sebocytes express functional TLR-2, TLR-4 and CD14. Upregulation of stearoyl-CoA desaturase (SCD) and fatty acid desaturase-2 (FADS2) expression induces pro-inflammatory sebaceous activity. On the other hand, corticotropin-releasing hormone (CRH) is likely to serve as an autocrine stress hormone in human sebocytes. In addition to its antiproliferative, lipogenetic and androgen-activating functions, CRH exhibits a pro-inflammatory action and its expression is upregulated in acne-involved sebaceous glands.
French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial
P.B. Lima, J.A.F. Dias, A.C.C. Esposito, L.D.B. Miot, H.A. Miot
doi : 10.1111/jdv.16896
Volume 35, Issue 2 p. 502-508
Melasma can be recalcitrant to treatment, and relapses are common. Pycnogenol has been reported to be effective in treating melasma.
Sexually transmitted infections’ epidemiology and knowledge, attitude and practice survey in a set of migrants attending the sexual health clinic in Malta
V. Padovese, A. Farrugia, S. Almabrok Ali Ghath, I. Rossoni
doi : 10.1111/jdv.16949
Volume 35, Issue 2 p. 509-516
The number of international migrants is estimated at 272 million people worldwide. In Europe, migrants face the disproportionate burden of infectious diseases, including hepatitis B and C, HIV and sexually transmitted infections (STIs). High-risk behaviours, sexual abuse, poor living conditions and barriers to accessing health care may affect migrants' sexual health, leading to infections.
Skin-Related complications of Klippel–Trenaunay Syndrome: a retrospective review of 410 patients
K.R. Anderson, H. Nguyen, J.J. Schoch, C.M. Lohse, D.J. Driscoll, M.M. Tollefson
doi : 10.1111/jdv.16999
Volume 35, Issue 2 p. 517-522
Little is known about skin-related complications in Klippel–Trenaunay syndrome (KTS), a complex vascular anomaly defined by capillary malformation (CM), venous malformation (VM) ± lymphatic malformation (LM) and limb overgrowth. Reported skin-related complications of KTS include ulceration, vascular ectasias (blebs), bleeding and infection.
Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatology-specific outcome taxonomy
T. Lange, J. Kottner, T. Weberschock, E. Hahnel, C. Apfelbacher, S. Brandstetter, A. Dreher, T. Datzmann, E. Burden-Teh, N.K. Rogers, P. Spuls, M.J. Grainge, L. Jacobi, H.C. Williams, J. Schmitt
doi : 10.1111/jdv.16854
Volume 35, Issue 2 p. 523-535
Standardized outcome reporting is crucial for trial evidence synthesis and translation of findings into clinical decision-making. The OMERACT 2.0 Filter and COMET outcome domain taxonomy propose frameworks for consistent reporting of outcomes. There is an absence of a uniform dermatology-specific reporting strategy that uses precise and consistent outcome definitions.
A machine learning-based, decision support, mobile phone application for diagnosis of common dermatological diseases
R. Pangti, J. Mathur, V. Chouhan, S. Kumar, L. Rajput, S. Shah, A. Gupta, A. Dixit, D. Dholakia, S. Gupta, S. Gupta, M. George, V.K. Sharma, S. Gupta
doi : 10.1111/jdv.16967
Volume 35, Issue 2 p. 536-545
The integration of machine learning algorithms in decision support tools for physicians is gaining popularity. These tools can tackle the disparities in healthcare access as the technology can be implemented on smartphones. We present the first, large-scale study on patients with skin of colour, in which the feasibility of a novel mobile health application (mHealth app) was investigated in actual clinical workflows.
Performance of a deep neural network in teledermatology: a single-centre prospective diagnostic study
C. Mu?oz-L?pez, C. Ram?rez-Cornejo, M.A. Marchetti, S. S. Han, P. Del Barrio-D?az, A. Jaque, P. Uribe, D. Majerson, M. Curi, C. Del Puerto, F. Reyes-Baraona, R. Meza-Romero, J. Parra-Cares, P. Araneda-Ortega, M. Guzm?n, R. Mill?n-Apablaza, M. Nu?ez-Mora, K. Liopyris, C. Vera-Kellet, C. Navarrete-Dechent
doi : 10.1111/jdv.16979
Volume 35, Issue 2 p. 546-553
The use of artificial intelligence (AI) algorithms for the diagnosis of skin diseases has shown promise in experimental settings but has not been yet tested in real-life conditions.
Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with intravenous immunoglobulin: ‘Killing 2 birds with one stone’
M. Saha, A. D’Cruz, N. Paul, R. Healy, D. Collins, D.-A. Charles, S. Sahu, A. Fonia
doi : 10.1111/jdv.16887
Volume 35, Issue 2 p. e97-e98
Comment on ‘Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19’: involvement of herpesvirus reactivations and adverse drug reactions in diverse cutaneous manifestations and overall disease severity of COVID-19
T. Shiohara, Y. Mizukawa
doi : 10.1111/jdv.16959
Volume 35, Issue 2 p. e98-e100
Why are chilblains underreported in Nordic countries during the COVID-19 pandemic? An analysis of Google Trends
N. Kluger
doi : 10.1111/jdv.16974
Volume 35, Issue 2 p. e100-e101
Clinical symptoms of hyperandrogenic women diagnosed with COVID-19
F.A. Cadegiani, R.K. Lim, A. Goren, J. McCoy, M. Situm, M. Kovacevic, S. Va?? Galv?n, R. Sinclair, A. Tosti, C.G. Wambier
doi : 10.1111/jdv.17004
Volume 35, Issue 2 p. e101-e104
Cutaneous symptoms of patients diagnosed with COVID-19 in one province: a cross-sectional survey
E. ?ksüm Solak, B. Baran Ketencioglu, H. Aslaner, S.L. ?inar, D. Kartal, A.R. Benli, M. Borlu
doi : 10.1111/jdv.16904
Volume 35, Issue 2 p. e105-e106
Cutaneous T-cell lymphoma after chronic exposure to hydrochlorothiazide: pharmacovigilance analysis from the RADAR (Research on Adverse Drug events And Reports) Program
D.R. Pease, M.E. Martinez-Escala, J. Jimenez, J. Guitart, D.P. West, B. Nardone
doi : 10.1111/jdv.16833
Volume 35, Issue 2 p. e106-e108
Six cases of chloracne in Italy: the success of combined therapy
M.A. Chessa, M. La Placa, A. Patrizi, A. Virdi, C. Misciali, G. Fedrizzi, F. Filippi, J.-H. Saurat, V. Tengattini, M.T. Caletti, A. Mazzotti, O. Sorg, F. Fontao, G. Kaya, I. Neri
doi : 10.1111/jdv.16835
Volume 35, Issue 2 p. e108-e111
Effectiveness of 308-nm excimer lamp in the treatment of notalgia paresthetica
P. Fonda-Pascual, C. Collantes-Rodriguez, L. Sanchez- Los Arcos, P. Fernandez-Gonzalez, M. Canseco-Martin, F. Alcantara-Nicolas, F. Rueda-Correa, S. Vidal-Asensi
doi : 10.1111/jdv.16836
Volume 35, Issue 2 p. e111-e113
Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases
V. Reymann, D. Bessis, B. Bergeret, D. Lipsker, A. Du-Thanh, N. Terrail, M. Dandurand, O. Dereure
doi : 10.1111/jdv.16839
Volume 35, Issue 2 p. e113-e115
Reactive angioendotheliomatosis revealing a glomerulopathy secondary to a monoclonal gammopathy successfully treated with lenalidomide
Y. Di Filippo, N. Cardot-Leccia, E. Long-Mira, M. Andreani, V. Richez, J.-P. Lacour, T. Passeron, H. Montaudié
doi : 10.1111/jdv.16840
Volume 35, Issue 2 p. e115-e118
Enigmatic swellings of the calf following herpes zoster – a case of induced lymphangiogenesis
S.B. Verma, R. Joshi, R. Wolf, U. Wollina
doi : 10.1111/jdv.16842
Volume 35, Issue 2 p. e118-e119
Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib
M.P. Konstantinou, P. Lucas, C. Uthurriague, M. Severino-Freire, N. Spenatto, C. Gaudin, L. Lamant, E. Tournier, C. Bulai-Livideanu, N. Meyer, C. Paul
doi : 10.1111/jdv.16850
Volume 35, Issue 2 p. e120-e121
Serum thymus and activation-regulated chemokine (TARC/CCL17) may be useful to predict the disease activity in patients with bullous pemphigoid
M. Suzuki, Y. Yamaguchi, K. Nakamura, M. Kanaoka, S. Matsukura, K. Takahashi, Y. Takahashi, T. Kambara, M. Aihara
doi : 10.1111/jdv.16851
Volume 35, Issue 2 p. e121-e124
Palmoplantar lichen planus-like lupus erythematosus keratoderma: an underrecognized and distinctive cutaneous manifestation of systemic or subacute lupus erythematosus
B. Bergeret, L.-P. Secco, V. Pallure, C. Daien, Y.-M. Pers, J. Gottlieb, S. Barete, C. Girard, D. Lipsker, D. Bessis, the Study Group of Systemic Diseases in Dermatology (EMSED: ?tude des Maladies Systémiques en Dermatologie)
doi : 10.1111/jdv.16852
Volume 35, Issue 2 p. e124-e126
Flag sign: the trichoscopic feature of white hair phenomenon in alopecia areata
A. Souissi, M. Ben Slimane, F. Alaoui, T. Bacha, F. Zeglaoui, M. Mokni
doi : 10.1111/jdv.16853
Volume 35, Issue 2 p. e126-e128
Prevalence of cardiac and metabolic diseases among patients with alopecia areata
R.R.Z. Conic, S. Chu, N.L. Tamashunas, G. Damiani, W. Bergfeld
doi : 10.1111/jdv.16864
Volume 35, Issue 2 p. e128-e129
Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials
L.A. Beck, J.I. Silverberg, E.L. Simpson, G. Yosipovitch, L. Eckert, I. Guillemin, Z. Chen, M. Ardeleanu, S. Plaum, N. Graham, M. Ruddy, G. Pirozzi, A. Gadkari
doi : 10.1111/jdv.16865
Volume 35, Issue 2 p. e130-e133
Demographic and clinical characteristics of extramammary Paget's disease patients in Japan from 2000 to 2019
F.M. Ghazawi, N. Iga, R. Tanaka, Y. Fujisawa, K. Yoshino, C. Yamashita, Y. Yamamoto, T. Fujimura, T. Yanagi, H. Hata, S. Matsushita, M. Le, S.F. Roy, F. Lagacé, Y. Ishida, K. Kabashima, A. Otsuka
doi : 10.1111/jdv.16868
Volume 35, Issue 2 p. e133-e135
MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project
I. Stefanaki, A.J. Stratigos, K.P. Kypreou, E. Evangelou, S. Gandini, P. Maisonneuve, D. Polsky, D. Lazovich, J. Newton-Bishop, P.A. Kanetsky, S. Puig, N.A. Gruis, P. Ghiorzo, C. Pellegrini, A. De Nicolo, G. Ribas, G. Guida, J.C. Garcia-Borron, M.C. Fargnoli, H. Nan, M.T. Landi, J. Little, F. Sera, S. Raimondi, for the M-SKIP Study Group
doi : 10.1111/jdv.16869
Volume 35, Issue 2 p. e135-e138
Prostaglandin analogue for treatment of eyebrow loss in frontal fibrosing alopecia: three cases with different outcomes
A. Murad, W. Bergfeld
doi : 10.1111/jdv.16870
Volume 35, Issue 2 p. e138-e140
Evidence for different immune signatures and sensitization patterns in sub-Saharan African vs. Central European atopic dermatitis patients
C.C.V. Lang, J. Masenga, G. Semango, H. Kaderbhai, N. Li, G. Tan, A. Heider, E. Guttman-Yassky, F. Grimm, P. Schmid-Grendelmeier, M.C. Brüggen
doi : 10.1111/jdv.16871
Volume 35, Issue 2 p. e140-e142
Characteristic pathological features of keratinocyte death in a case of Stevens–Johnson syndrome manifested by an immune checkpoint inhibitor
H. Kimura, A. Hasegawa, I. Takei, T. Kawai, Y. Tsuchida, Y. Abe, R. Hayashi, N. Hama, R. Abe
doi : 10.1111/jdv.16872
Volume 35, Issue 2 p. e142-e145
Terbinafine-induced DRESS syndrome mimicking eosinophilic cellulitis
V. Rajagopal Srinivasan, S. Singh, J.N. Bharti, D. Vedant
doi : 10.1111/jdv.16873
Volume 35, Issue 2 p. e145-e147
Flag-like hypermelanosis with superimposed lichen sclerosus et atrophicus: an unusual Koebner phenomenon?
P. Sharma, S. Sonthalia, R. Happle
doi : 10.1111/jdv.16877
Volume 35, Issue 2 p. e147-e149
Peri-and intraneural mucinosis in painful, interstitial granuloma annulare of the digit
V. Caputo, E. Bonoldi, F. Rongioletti
doi : 10.1111/jdv.16880
Volume 35, Issue 2 p. e149-e151
Concurrent benign tertiary syphilis and asymptomatic neurosyphilis in an immunocompetent patient
E. Cozzani, G. Gasparini, G. Ciccarese, F. Drago, I. Trave, V. Vellone, C.M. Biatta, F. Cabiddu, G. Ribizzi, A. Parodi
doi : 10.1111/jdv.16882
Volume 35, Issue 2 p. e151-e152
Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling
K. Sü?muth, H. Traupe, K. Loser, S. St?nder, C. Kessel, H. Wittkowski, V. Oji
doi : 10.1111/jdv.16883
Volume 35, Issue 2 p. e152-e155
Carrying out local care for epidermal necrolysis: survey of practices
S. Ingen-Housz-Oro, R. Le Floch, A. Alves, A. Colin, R. Ouedraogo, A. Welfringer, O. Dereure, N. Besnard, C. Bodemer, C. Bernier, C. Hoffmann, F. Tétart, D. Carpentier, N. Cordel, E. Elie, M. Tauber, L. Soubiron, B. Milpied, N. de Prost
doi : 10.1111/jdv.16884
Volume 35, Issue 2 p. e155-e157
Serum heat shock protein 27 levels in patients with systemic sclerosis: a possible biomarker of skin sclerosis
K.M. Matsuda, A. Yoshizaki, H. Kotani, Y. Norimatsu, A. Kuzumi, M. Fukayama, T. Fukasawa, S. Ebata, A. Yoshizaki-Ogawa, Y. Asano, K. Oba, S. Sato
doi : 10.1111/jdv.16885
Volume 35, Issue 2 p. e157-e159
Itchy plaques on trunk and feet in a patient with dark skin: a case of Dystrophic Calcinosis Cutis superimposed on Lichen Simplex Chronicus
F. Bardazzi, C. Misciali, L. Sacchelli, V. Evangelista
doi : 10.1111/jdv.16886
Volume 35, Issue 2 p. e159-e160
Methylation in psoriasis. Does sex matter?
M. Llamas-Velasco, A. Reolid, A. Sanz-Garc?a, L. Alonso-Guirado, J. Garc?a-Mart?nez, P. S?nchez-Jiménez, E. Mu?oz-Aceituno, E. Daudén, F. Abad-Santos, M.C. Ovejero-Benito
doi : 10.1111/jdv.16888
Volume 35, Issue 2 p. e161-e163
